An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort

An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort

By understanding prognostic biomarkers, we gain insights into disease biology and may improve design, conduct, and data analysis of clinical trials and real-world data. In this context, we used the Flatiron Health Electronic Health Record-derived deidentified database that provides treatment outcome...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 31; no. 11; pp. 1561 - 1568
Main Authors: Becker, T., Weberpals, J., Jegg, A.M., So, W.V., Fischer, A., Weisser, M., Schmich, F., Rüttinger, D., Bauer-Mehren, A.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-11-2020
Subjects:
Carcinoma, Non-Small-Cell Lung
Cohort Studies
Cox regression
Flatiron Health
Humans
Lung Neoplasms
overall survival
Prognosis
prognostic score (ROPRO)
real world data (RWD)
Retrospective Studies
real world data (RWD)
overall survival
Cox regression
Flatiron Health
prognostic score (ROPRO)
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By understanding prognostic biomarkers, we gain insights into disease biology and may improve design, conduct, and data analysis of clinical trials and real-world data. In this context, we used the Flatiron Health Electronic Health Record-derived deidentified database that provides treatment outcome and biomarker data from >280 oncology centers in the USA, organized into 17 cohorts defined by cancer type. In 122 694 patients, we analyzed demographic, clinical, routine hematology, and blood chemistry parameters within a Cox proportional hazard framework to derive a multivariable prognostic risk model for overall survival (OS), the ‘Real wOrld PROgnostic score (ROPRO)’. We validated ROPRO in two independent phase I and III clinical studies. A total of 27 variables contributed independently and homogeneously across cancer indications to OS. In the largest cohort (advanced non-small-cell lung cancer), for example, patients with elevated ROPRO scores (upper 10%) had a 7.91-fold (95% confidence interval 7.45–8.39) increased death hazard compared with patients with low scores (lower 10%). Median survival was 23.9 months (23.3–24.5) in the lowest ROPRO quartile Q1, 14.8 months (14.4–15.2) in Q2, 9.4 months (9.1–9.7) in Q3, and 4.7 months (4.6–4.8) in Q4. The ROPRO model performance indicators [C-index = 0.747 (standard error 0.001), 3-month area under the curve (AUC) = 0.822 (0.819–0.825)] strongly outperformed those of the Royal Marsden Hospital Score [C-index = 0.54 (standard error 0.0005), 3-month AUC = 0.579 (0.577–0.581)]. We confirmed the high prognostic relevance of ROPRO in clinical Phase 1 and III trials. The ROPRO provides improved prognostic power for OS. In oncology clinical development, it has great potential for applications in patient stratification, patient enrichment strategies, data interpretation, and early decision-making in clinical studies. •Clinical routine variables can be combined into a high-quality prognostic score [Real wOrld PROgnostic score (ROPRO)] for overall survival.•ROPRO can be used for patient matching and baseline risk adjustment in clinical studies.•ROPRO can support patient enrichment in early clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.07.013